Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Nat Rev Microbiol. 2017 Feb 27;15(4):217–231. doi: 10.1038/nrmicro.2016.193

Figure 3. Molecular targets in trypanosomatids.

Figure 3

a | trypanosomatids show unique metabolic pathways and cellular functions that are attractive for drug discovery. Many enzymes are divergent from other eukaryotes and they have unique or highly specialized organelles such as the kinetoplast and the glycosome, respectively. b | For some antitrypansomatid compounds the molecular targets are known. DDD85646 targets N-myristoyltransferase (NMT); posaconazole and ravuconazole are CYP51 inhibitors; K777 irreversibly inhibits the cysteine protease cruzipain; and GNF6702 selectively inhibits the trypanosomatid proteasome.